Biomarkers To Define The Treatment End-point For Pulmonary Exacerbations In Cystic Fibrosis
Funder
National Health and Medical Research Council
Funding Amount
$1,031,371.00
Summary
Sensitive and reliable tests are required to monitor lung disease severity in cystic fibrosis. A number of potential methods have emerged in recent years. We will investigate how these tests track an acute episode of lung disease and determine whether, following a typical course of treatment, there is evidence of residual damage that contributes to overall progression of lung disease.